RecruitingNot ApplicableNCT05237258

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Sponsor

Massachusetts General Hospital

Enrollment

2,300 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Relapsed Adult AML Primary Refractory Acute Myeloid Leukemia

Summary

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Eligibility

Min Age: 18 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether specialty palliative care (comfort-focused support) or oncology-delivered palliative care better helps patients with high-risk acute myeloid leukemia (a blood cancer) manage their symptoms and quality of life. You may be eligible if... - You are a hospitalized adult (18 or older) with high-risk acute myeloid leukemia (AML) - You are starting intensive chemotherapy or certain other treatments - Caregivers who are adults living with or having regular in-person contact with a participating patient may also qualify You may NOT be eligible if... - You have a specific subtype of AML called acute promyelocytic leukemia (APML) - You are receiving supportive care only, without active treatment - You have conditions that prevent giving informed consent - You have already seen a palliative care specialist during two hospitalizations in the past 6 months - You are expected to be discharged within 2 days Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALSpecialty Palliative Care

Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.

BEHAVIORALPrimary Palliative Care

Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.

Locations(20)

University of Alabama - Birmingham

Birmingham, Alabama, United States

Stanford University

Stanford, California, United States

University of Colorado Denver I Anschutz Medical Campus

Denver, Colorado, United States

University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Northwestern University

Evanston, Illinois, United States

Indiana University

Bloomington, Indiana, United States

Johns Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

University of Rochester

Rochester, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Duke University

Durham, North Carolina, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

University of Wisconsin

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05237258

Related Trials

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

NCT066492271 location

Novel Digital Application for Patients With Acute Leukemia

NCT064721283 locations

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

NCT063070541 location

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

NCT053058591 location

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT0385057434 locations